Cargando…

Impact of rosiglitazone meta-analysis on use of glucose-lowering medications

BACKGROUND: In May 2007 Nissen and Wolski reported the results of a meta-analysis showing an association between use of rosiglitazone and increased risk of myocardial infarction (N Engl J Med 2007;356(24):2457–2471). Rosiglitazone is an insulin-sensitizing agent used to control blood glucose levels...

Descripción completa

Detalles Bibliográficos
Autores principales: Morrow, Richard L, Carney, Greg, Wright, James M, Bassett, Ken, Sutherland, Jenny, Dormuth, Colin R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Open Medicine Publications, Inc. 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116669/
https://www.ncbi.nlm.nih.gov/pubmed/21686295
_version_ 1782206267989688320
author Morrow, Richard L
Carney, Greg
Wright, James M
Bassett, Ken
Sutherland, Jenny
Dormuth, Colin R
author_facet Morrow, Richard L
Carney, Greg
Wright, James M
Bassett, Ken
Sutherland, Jenny
Dormuth, Colin R
author_sort Morrow, Richard L
collection PubMed
description BACKGROUND: In May 2007 Nissen and Wolski reported the results of a meta-analysis showing an association between use of rosiglitazone and increased risk of myocardial infarction (N Engl J Med 2007;356(24):2457–2471). Rosiglitazone is an insulin-sensitizing agent used to control blood glucose levels in patients with type 2 diabetes. Subsequent analyses provided evidence that the meta-analysis led to a decline in new and prevalent use of rosiglitazone. We sought to evaluate the impact of the meta-analysis on patterns of use of glucose-lowering drugs and patterns of initiation, cessation and switching of drug therapy, and to estimate these effects in relation to other predictors of initiation and cessation of rosiglitazone. METHODS: We used an interrupted time series analysis to test the impact of the meta-analysis on monthly utilization of glucose-lowering drugs for the 4.3 million residents of the province of British Columbia. We used multivariate logistic regression with generalized estimating equations to test predictors of initiation and cessation of rosiglitazone, including the influence of microvascular and macrovascular comorbidities, before and after the meta-analysis. RESULTS: A comparison of predicted and observed utilization for November 2007 showed that use of rosiglitazone declined by 40% (95% confidence interval 39%–42%), whereas use of pioglitazone, insulin and sulfonylureas increased. The presence of macrovascular comorbidities strengthened both the negative impact of the meta-analysis on initiation of rosiglitazone therapy and the positive impact of the meta-analysis on cessation of this drug. INTERPRETATION: The shift in utilization from rosiglitazone to insulin and sulfonylureas and the modest increase in use of pioglitazone suggest that the latter drug was not embraced as a less harmful alternative to rosiglitazone. Macrovascular comorbidities played a greater role in decisions to start or stop rosiglitazone therapy after the meta-analysis was published.
format Online
Article
Text
id pubmed-3116669
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Open Medicine Publications, Inc.
record_format MEDLINE/PubMed
spelling pubmed-31166692011-06-16 Impact of rosiglitazone meta-analysis on use of glucose-lowering medications Morrow, Richard L Carney, Greg Wright, James M Bassett, Ken Sutherland, Jenny Dormuth, Colin R Open Med Research BACKGROUND: In May 2007 Nissen and Wolski reported the results of a meta-analysis showing an association between use of rosiglitazone and increased risk of myocardial infarction (N Engl J Med 2007;356(24):2457–2471). Rosiglitazone is an insulin-sensitizing agent used to control blood glucose levels in patients with type 2 diabetes. Subsequent analyses provided evidence that the meta-analysis led to a decline in new and prevalent use of rosiglitazone. We sought to evaluate the impact of the meta-analysis on patterns of use of glucose-lowering drugs and patterns of initiation, cessation and switching of drug therapy, and to estimate these effects in relation to other predictors of initiation and cessation of rosiglitazone. METHODS: We used an interrupted time series analysis to test the impact of the meta-analysis on monthly utilization of glucose-lowering drugs for the 4.3 million residents of the province of British Columbia. We used multivariate logistic regression with generalized estimating equations to test predictors of initiation and cessation of rosiglitazone, including the influence of microvascular and macrovascular comorbidities, before and after the meta-analysis. RESULTS: A comparison of predicted and observed utilization for November 2007 showed that use of rosiglitazone declined by 40% (95% confidence interval 39%–42%), whereas use of pioglitazone, insulin and sulfonylureas increased. The presence of macrovascular comorbidities strengthened both the negative impact of the meta-analysis on initiation of rosiglitazone therapy and the positive impact of the meta-analysis on cessation of this drug. INTERPRETATION: The shift in utilization from rosiglitazone to insulin and sulfonylureas and the modest increase in use of pioglitazone suggest that the latter drug was not embraced as a less harmful alternative to rosiglitazone. Macrovascular comorbidities played a greater role in decisions to start or stop rosiglitazone therapy after the meta-analysis was published. Open Medicine Publications, Inc. 2010-03-16 /pmc/articles/PMC3116669/ /pubmed/21686295 Text en http://creativecommons.org/licenses/by-nc-sa/2.5/ca/ Open Medicine applies the Creative Commons Attribution Share Alike License, which means that anyone is able to freely copy, download, reprint, reuse, distribute, display or perform this work and that authors retain copyright of their work. Any derivative use of this work must be distributed only under a license identical to this one and must be attributed to the authors. Any of these conditions can be waived with permission from the copyright holder. These conditions do not negate or supersede Fair Use laws in any country.
spellingShingle Research
Morrow, Richard L
Carney, Greg
Wright, James M
Bassett, Ken
Sutherland, Jenny
Dormuth, Colin R
Impact of rosiglitazone meta-analysis on use of glucose-lowering medications
title Impact of rosiglitazone meta-analysis on use of glucose-lowering medications
title_full Impact of rosiglitazone meta-analysis on use of glucose-lowering medications
title_fullStr Impact of rosiglitazone meta-analysis on use of glucose-lowering medications
title_full_unstemmed Impact of rosiglitazone meta-analysis on use of glucose-lowering medications
title_short Impact of rosiglitazone meta-analysis on use of glucose-lowering medications
title_sort impact of rosiglitazone meta-analysis on use of glucose-lowering medications
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116669/
https://www.ncbi.nlm.nih.gov/pubmed/21686295
work_keys_str_mv AT morrowrichardl impactofrosiglitazonemetaanalysisonuseofglucoseloweringmedications
AT carneygreg impactofrosiglitazonemetaanalysisonuseofglucoseloweringmedications
AT wrightjamesm impactofrosiglitazonemetaanalysisonuseofglucoseloweringmedications
AT bassettken impactofrosiglitazonemetaanalysisonuseofglucoseloweringmedications
AT sutherlandjenny impactofrosiglitazonemetaanalysisonuseofglucoseloweringmedications
AT dormuthcolinr impactofrosiglitazonemetaanalysisonuseofglucoseloweringmedications